ArticleCureus2026
High-Altitude Headache Resolving After Self-Administration of Goreisan: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
High-altitude headache (HAH) is the most common neurological manifestation of rapid ascent to high altitude and may occur independently or as part of acute mountain sickness (AMS). Although simple analgesics are commonly used for symptomatic treatment, evidence regarding alternative therapeutic options remains limited. Goreisan, a traditional Japanese Kampo medicine, has been reported to regulate body fluid homeostasis through aquaporin modulation and may influence cerebral fluid dynamics. However, to our knowledge, its use for HAH has not previously been reported. We herein describe a 34-year-old Japanese man with a history of migraine and hypertension, who developed a headache clinically consistent with HAH that resolved after oral administration of Goreisan. He developed a right unilateral headache approximately 90 minutes after rapid ascent from Lima (150 m) to Cusco, Peru (3,400 m). The clinical presentation was consistent with the International Classification of Headache Disorders, 3rd edition criteria for HAH, although an altitude-triggered migraine attack could not be completely excluded. Because no analgesics were available, he self-administered 2.5 g of Goreisan. The headache began to improve within 30 minutes, decreased from 4/10 to 1/10 on the Numerical Rating Scale within one hour, and resolved completely within two hours without additional medication. No recurrence occurred during the remainder of his 10-day stay, and he was able to undertake hiking activities the following day. Although improvement occurred temporally after Goreisan administration, spontaneous improvement or early acclimatization cannot be excluded, and causality cannot be established from this single case. This observation supports prospective evaluation of Goreisan in patients with HAH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.